Establishment of In Vitro P-Glycoprotein Inhibition Assay and Its Exclusion Criteria to Assess the Risk Of Drug–Drug Interaction at the Drug Discovery Stage

Abstract

The decision tree to determine whether the P-glycoprotein (P-gp)/multidrug resistance protein 1 (MDR1)-mediated drug–drug interaction (DDI) study is recommended has been proposed by the International Transporter Consortium. We, therefore, designed an in vitro P-gp inhibition assay and determined the appropriate risk criteria for P-gp-mediated DDI at the drug discovery stage. Effects of P-gp inhibitors on digoxin transport across a monolayer of MDR1-expressing cells were examined. The IC50 (half-maximal inhibitory concentration) values generated from the efflux ratio (ER) were smaller than those generated from basolateral-to-apical directional apparent permeability. The difference in IC50 values was kinetically described in a compartment model analysis. This analysis indicated that ER is a highly sensitive parameter that can be used for the degree of P-gp inhibition. Considering IC50 values and the increase in digoxin exposure in clinical DDI studies, the risk criteria of [I2]/IC50 = 30 ([I2], theoretically maximal gastrointestinal concentration) was the optimal cutoff value to predict a clinically relevant DDI. We also investigated whether the IC50 value itself is applicable to assess the DDI risk. In conclusion, compounds with IC50 values less than 2 μM exhibit high risk for P-gp-mediated DDIs. However, compounds with IC50 values greater than or equal to 2 μM are inconclusive because clinical doses should be considered for the precise DDI risk assessment. © 2011 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:4013–4023, 2011